Regeneron beats Q2 expectations on Dupixent, high-dose Eylea
REGN Regeneron Pharmaceuticals Inc
$696.28 +0.16%
차트·분석 보기 → - 1Regeneron (REGN) beats Q2 revenue and earnings expectations on strong Dupixent and high-dose Eylea
- 2Revenue $4.29B, adjusted EPS $14.29; Dupixent net sales reach approximately $6B
- 3RBC expects improved H2 results on solid commercial performance and margin improvement from Sanofi development balance repayment
This 3-line summary is compiled from the report below.
Reuters View original ↗🎯 오늘의 AI 픽 5종목, 무료로 전부 공개합니다
숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다